Is it possible to combine zodak and alcohol? Methods of using various forms of the drug. Features of using Zodak

COMPOSITION AND FORM OF RELEASE:

table p/o 10 mg, No. 5, No. 7

table p/o 10 mg, No. 10 7.99 UAH.

table p/o 10 mg, No. 30 16.5 UAH.

table p/o 10 mg, No. 60, No. 90, No. 100

Cetirizine hydrochloride 10 mg

No. UA/4070/03/01 from 03/22/2006 to 03/22/2011

cap. d/oral. approx. 10 mg/ml vial. 20 ml, No. 1 17.85 UAH.

Cetirizine 10 mg/ml

Other ingredients: methylparaben, propylparaben, glycerol 85%, propylene glycol, sodium saccharin, sodium acetate, acetic acid, purified water.

No. UA/4070/01/01 from 01/23/2006 to 01/23/2011

syrup 5 mg/5 ml vial. 100 ml, No. 1 20.7 UAH.

Cetirizine dihydrochloride 5 mg/5 ml

Other ingredients: methylparaben, propylparaben, glycerol 85%, propylene glycol, sorbitol syrup, sodium saccharin, sodium acetate, acetic acid, banana flavor, purified water.

No. UA/4070/02/01 from 01/23/2006 to 01/23/2011

PHARMACOLOGICAL PROPERTIES: Cetirizine is a second generation antihistamine with a prolonged action. Selective inhibitor peripheral H1 receptors, does not have pronounced anticholinergic and antiserotonin activity. In therapeutic doses, the drug exhibits virtually no sedative activity and does not cause drowsiness. Cetirizine affects the early histamine-dependent stage allergic reactions and at the late cellular stage, inhibits the release of histamine from fat cells and basophilic leukocytes, reduces the migration of inflammatory cells, primarily eosinophils.

Cetirizine exhibits linear kinetics in the dose range of 5–60 mg. The terminal half-life is approximately 10 hours and the total volume of distribution is 0.50 l/kg. After reception daily dose 10 mg for 10 days, no accumulation effect of cetirizine was noted. At steady state, the maximum level of the drug in the blood plasma is 300 ng/ml and is achieved within 1.0±0.5 hours. Cetirizine binds to plasma proteins in an amount of 93±0.3%. Cetirizine does not affect the binding of warfarin to plasma proteins.

During its initial passage through the liver, cetirizine is not actively metabolized. About 2/3 of the substance is excreted unchanged in the urine. In a study on volunteers, no differences in pharmacokinetic parameters such as maximum concentration and AUC were observed. There were no differences in the kinetics of cetirizine in adults depending on race.

Food intake does not affect the amount of absorption of cetirizine, but the rate of absorption is reduced. The bioavailability of cetirizine is the same for any form of the drug: drops, syrup and tablets.

INDICATIONS: symptomatic treatment of seasonal allergic rhinitis and allergic perennial rhinitis, as well as symptoms allergic conjunctivitis. Treatment of various types of itching and urticaria, including chronic idiopathic urticaria (hives accompanied by fever).

APPLICATION:Zodak tablets

Children aged 6 to 12 years: 1/2 tablet (5 mg of cetirizine) 2 times a day or 1 tablet (10 mg) 1 time a day.

Children over 12 years old and adults: 1 tablet (10 mg) 1 time per day.

The tablet should be taken whole, without chewing, with water.

Drops Zodak

Children aged 1–2 years: 2.5 mg (5 drops) 2 times a day .

Children aged 2–6 years: 2.5 mg (5 drops) 2 times a day or 5 mg (10 drops) 1 time a day.

Children aged 6–12 years: 5 mg (10 drops) 2 times a day or 10 mg (20 drops) 1 time a day.

Children V age 10 mg (20 drops) 1 time per day.

The dose is measured by the number of drops; 1 ml contains 20 drops.

Syrup Zodak

Children aged 1–2 years: 1/2 scoop (2.5 mg) 2 times a day .

Children aged 2–6 years: 1/2 measuring spoon (2.5 mg) 2 times a day in the morning and evening or 1 measuring spoon (5 mg) 1 time per day.

Children aged 6–12 years: 1 measuring spoon (5 mg) 2 times a day in the morning and evening or 2 measuring spoons (10 mg) 1 time a day.

Children V age over 12 years old, teenagers and adults: 2 scoops (10 mg) 1 time per day.

The dose is measured with a measuring spoon marked 1/4 (1.25 ml) and 1/2 (2.5 ml); a spoon contains 5 ml of syrup.

Elderly patients: given that normal function kidneys, according to existing data there is no need to reduce the dose in elderly patients.

Patients with moderate or severe renal impairment: The intervals between doses should be adjusted individually, depending on the state of renal function. The data given in the table allows you to adjust the dose depending on the patient's creatinine clearance (CL cr) in ml/min. The CL cr value (ml/min) can be calculated from the determined serum creatinine (mg/dl) using the following formula:

Dosage adjustments for adult patients with impaired renal function:

For children with renal failure, the dose should be selected individually, taking into account the patient's creatinine clearance and body weight.

Patients with impaired liver function: there is no need to adjust the dose.

Patients with liver and kidney damage: Dose adjustment is recommended (see “Patients with impaired renal function”).

CONTRAINDICATIONS:increased sensitivity a history of cetirizine or hydroxyzine or any other components of the drug; patients with severe renal impairment with creatinine clearance below 10 ml/min; during pregnancy and lactation. Age up to 1 year (syrup). Age up to 6 years (tablets).

SIDE EFFECTS: In contrast to previous H1 receptor antagonists, cetirizine penetrates the central nervous system to a lesser extent, resulting in a noticeably lower sedative effect. Clinical researches indicate that at recommended doses side effects CNS effects of cetirizine are moderate, including drowsiness, fatigue, dizziness and headache. In some cases, there have been reports of paradoxical stimulation of the central nervous system.

Although cetirizine is a selective peripheral H1 receptor antagonist and does not have a significant anticholinergic effect, there have been reports of paradoxical stimulation of the central nervous system in some cases, and isolated reports of difficulty urinating, impaired ocular accommodation and a feeling of dry mouth. There have also been cases of liver dysfunction with increased levels of liver enzymes, accompanied by increased bilirubin levels. In most cases, these symptoms disappeared after stopping treatment with the drug.

SPECIAL INSTRUCTIONS: at therapeutic doses, no clinically significant interaction with alcohol was observed (at a blood alcohol concentration of 0.5 g/l). However, you should not drink alcohol during treatment with the drug.

Zodak does not provide sedative effect, typical for many antihistamines, but persons whose work requires increased attention and speed of reaction (for example, driving vehicles, servicing machines, working at heights, etc.) should be careful and not exceed the recommended dose.

INTERACTIONS: pharmacokinetic studies did not reveal any interaction of cetirizine with pseudoephedrine, cimetidine, ketoconazole, erythromycin and azithromycin. Repeated administration of theophylline (400 mg 1 time per day) and cetirizine affects the clearance of cetirizine, causing a slight decrease (16%); with simultaneous use of cetirizine and theophylline, the elimination of theophylline did not change.

Research at joint reception cetirizine and cimetidine, glipizide, diazepam and pseudoephedrine did not reveal any adverse pharmacodynamic interactions.

Concomitant use of cetirizine and azithromycin, erythromycin, ketoconazole, theophylline and pseudoephedrine does not cause any adverse clinical interactions. In particular, simultaneous use with macrolides or ketoconazole did not lead to clinically significant changes on the ECG.

Cetirizine does not affect the binding of warfarin to plasma proteins.

Eating does not reduce the amount of absorption of cetirizine, but the rate of absorption decreases.

OVERDOSE: symptoms that occur with a significant overdose of cetirizine are associated primarily with effects on the central nervous system or with manifestations of an anticholinergic effect.

Negative symptoms reported after five times the dose: agitation, diarrhea, dizziness, fatigue, headache, nausea, dilated pupils, itching, nervousness, sedation, drowsiness, stupor, tachycardia, tremor and urinary retention.

Treatment: A specific antidote for cetirizine is not known. In case of overdose, symptomatic and supportive therapy is recommended, it is necessary to rinse the stomach as quickly as possible. Hemodialysis is ineffective due to the high degree of binding of the drug to plasma proteins.

STORAGE CONDITIONS: under normal conditions.

Date added: 11/09/2006
Date modified: 10/10/2007

Information provided on medicines is intended for doctors and healthcare workers and includes materials from publications from different years. The publisher is not responsible for possible negative consequences resulting from improper use of the information provided. Any information presented on the site does not replace medical advice and cannot serve as a guarantee positive effect medicine.
The site does not distributes medicines. PRICES for drugs are approximate and may not always be relevant.
You can find the originals of the presented materials on the websites and

Name:

Zodac

Pharmachologic effect:

Zodak is a 2nd generation antiallergic drug with a prolonged effect. The active ingredient of the drug is cetirizine dihydrochloride, a selective blocker of peripheral H1 receptors. Does not have significant antiserotonin and anticholinergic effects. When used in therapeutic doses, Zodak does not cause sedation, including drowsiness. The active substance of Zodak affects the histamine-dependent - early phase of allergic reactions, as well as the late cellular phase. Under the influence of cetirizine, the release of histamine from basophils is inhibited and mast cells, decreased migration of eosinophils and other cells. When taking 5–60 mg of cetirizine, linear kinetics are observed. The total volume of distribution is 0.50 l/kg. The half-life of the active substance is 10 hours. The amount of absorption is not affected by food intake, but the rate of absorption of cetirizine is reduced.

There was no accumulation effect when taking a dose of 10 mg every day for 10 days. The maximum concentration in blood plasma after reaching equilibrium concentration is 300 ng/ml, which is achieved after 60±30 minutes. 93±0.3% of cetirizine is bound by blood proteins. It has no effect on the binding of warfarin to plasma proteins. It does not undergo active metabolic transformation during the initial passage through the liver. Approximately 2/3 of cetirizine is excreted unchanged in the urine. A study on volunteers revealed the absence of pharmacokinetic differences in both AUC and maximum concentration values. No differences in pharmacokinetic parameters were observed in adults of different racial backgrounds. The bioavailability of the active substance is the same for everyone dosage forms preparation: syrup, drops and tablets.

Indications for use:

· Therapy of itching and urticaria of various origins, including urticaria accompanied by fever (chronic idiopathic urticaria),

· symptomatic therapy allergic seasonal rhinitis and year-round allergic rhinitis,

· symptomatic treatment of allergic conjunctivitis.

Method of application:

Zodak tablets

The tablet is taken with water, regardless of food. Do not chew! For adults and children over 12 years of age – 10 mg/day (1 tablet) in 1 dose.

In pediatrics: children from 6 to 12 years old - 5 mg / day (1/2 tablet) 2 times / day, 10 mg of Zodak can be taken once a day.

Zodak-drops

For adults and children over 12 years old – 10 mg (20 drops) 1 time per day. 1 ml of the drug contains 20 drops.

In pediatrics: from the first days of life to 2 years - 5 drops (2.5 mg) 2 times / day, from 2 to 6 years - 5 drops (2.5 mg cetirizine) 2 times / day, 10 doses can be used drops (5 mg)

1 r / day, from 6 to 12 years - 10 drops (5 mg) 2 r / day, you can take 20 drops (10 mg) 1 r / day.

Zodak syrup

For adults and children over 12 years old – 10 mg (2 scoops) 1 time per day. 1 measuring spoon contains 5 ml of Zodak syrup. The spoon is equipped with divisions: ¼ - corresponds to 1.25 ml of syrup and ½ - 2.5 ml.

In pediatrics: from 1 to 2 years - 2.5 mg (half a measuring spoon) 2 times / day, from 2 to 6 years - 2.5 mg (half a measuring spoon) 2 times / day, 5 mg can be taken (1 measuring spoon) 1 r/day, from 6 to 12 years – 5 mg (1 measuring spoon) 2 r/day, you can take 10 mg (2 measuring spoons) 1 r/day.

Treatment of elderly patients

In the case of normally functioning kidneys, there is no need to reduce the dosage.

Treatment of patients with kidney dysfunction

With average or severe violations renal functions, individual intervals for taking Zodak should be established, which depends on the severity of renal failure: with minor violations(creatinine clearance - 50–79 ml/min) – there is no need for dose adjustment and change in the interval between doses, for mild disorders (creatinine clearance 30–49 ml/min) – 5 mg/day as usual, for severe disorders ( creatinine clearance ≤ 30 ml/min) – 10 mg once a day after 2 days, in terminal stage if there are contraindications to hemodialysis (creatinine clearance ≤ 10 ml/min), the use of Zodak is contraindicated.

The dose of cetirizine for children with renal insufficiency is calculated individually, based on body weight and creatinine clearance level.

Treatment of patients with liver dysfunction

There is no need to reduce the dosage.

Adverse events:

Unlike antihistamines previous generations that belong to the group of H1 receptor antagonists, active substance Zodaka penetrates the blood-brain barrier in small quantities, so the development of a sedative effect is not pronounced or very pronounced. mild degree. Although cetirizine acts selectively on peripheral H1 receptors, the anticholinergic effect is weak, but there have been reports of ocular accommodation disturbances, difficulty urinating, paradoxical stimulation of the central nervous system and a feeling of dry mouth.

From the central and peripheral nervous system:

fatigue, drowsiness, dizziness and headache, paradoxical stimulation of the nervous system - in isolated cases.

From the hepatobiliary system:

increase in bilirubin content and liver enzyme activity (indicated side effects transient and disappeared after discontinuation of the drug).

Contraindications:

Common to all dosage forms:

a history of hypersensitivity to hydroxyzine or cetirizine or to any other ingredients of Zodak,

· During pregnancy and breastfeeding,

· renal failure when the creatinine clearance level is less than 10 ml/min.

For tablets – age up to 6 years.

For syrup – age up to 1 year.

During pregnancy:

Zodak is contraindicated during pregnancy in all trimesters. If Zodak is prescribed to a nursing mother, breast-feeding temporarily stopped.

Interaction with other drugs:

Studies of the pharmacokinetic parameters of the interaction of cetirizine with cimetidine, pseudoephedrine, ketoconazole, azithromycin and erythromycin did not reveal. There is a slight decrease in the clearance of cetirizine to 16% when combined with repeated doses of theophylline at a dosage of 400 mg/day. Moreover, with this combination, the excretion of theophylline does not change.

Studies of pharmacodynamic parameters when combining cetirizine with glipizide, diazepam, azithromycin, theophylline, ketoconazole, erythromycin and pseudoephedrine did not reveal any adverse clinically significant interactions. Thus, the combination of the drug with ketoconazole or macrolides did not cause clinical significant changes electrocardiographic profile. It was also found that the active substance of Zodak does not affect the ability of warfarin to bind to blood proteins. At simultaneous administration food together with cetirizine, the volume of absorption does not change, but the rate of absorption decreases.

Overdose:

If the recommended dose of Zodak is exceeded, symptoms develop, mainly associated with changes in the central nervous system, anticholinergic effects of cetirizine are also likely. As a result of exceeding the dose by 5 times, there are reports of the following symptoms overdose: diarrhea, excitement, dizziness, nausea, fatigue, dilated pupils, headache, itching, sedation, nervousness, drowsiness, tachycardia, stupor, tremor and urinary retention.

No specific antidote has been identified. In case of overdose, supportive and symptomatic therapy is used. Immediately after taking large dose Gastric lavage is recommended. Hemodialysis is not effective because cetirizine is mostly bound to blood proteins.

Release form of the drug:

Zodak tablets – 10 mg, 5, 10, 30, 60, 90 pieces in blister packs. Pills white, oblong shape, biconvex, with a notch on 1 side.

Zodak-drops for internal reception– 10 mg in 1 ml, in 20 ml bottles. The drops are transparent, without color or with a slight yellow tint.

Zodak syrup – 5 mg/ml, 100 ml bottle. The syrup is transparent, without color or with a slight yellow tint. Has a characteristic banana smell.

Storage conditions:

At room temperature. Approved for over-the-counter release.

Compound:

Zodak tablets

Inactive ingredients: corn starch, lactose monohydrate, povidone, hydroxypropyl methylcellulose, titanium dioxide, talc, magnesium stearate, macrogol, dimethicone emulsion.

Zodak-drops

Active substance: cetirizine.

Inactive substances: propylparaben, methylparaben, glycerol 85%, sodium acetate, sodium saccharin, acetic acid, propylene glycol, purified water.

Zodak syrup

Active substance: cetirizine dihydrochloride.

Inactive ingredients: propylparaben, methylparaben, propylene glycol, glycerol 85%, sorbitol syrup, sodium acetate, sodium saccharin, banana flavor, acetic acid, purified water.

Additionally:

Tests have shown that Zodak has no clinically significant interaction with alcohol (in the case of a blood alcohol content of 0.5 g/l). However, it is not recommended to drink alcohol while taking Zodak. It is recommended to exercise caution for people whose activities involve increased demands on attention and quick reactions(drivers, machinists, machine maintenance, work at height, etc.). They also cannot exceed determined by the doctor dose.

Drugs with similar effects:

Cetrilev Aleric Xyzal Lorizan Psilo-balsam

Dear doctors!

If you have experience in prescribing this drug to your patients, share the result (leave a comment)! Did this medicine help the patient, did any side effects occur during treatment? Your experience will be of interest to both your colleagues and patients.

If you were prescribed this medicine and completed a course of therapy, tell us whether it was effective (helped), whether there were any side effects, what you liked/disliked. Thousands of people search the Internet for reviews of various medications. But only a few leave them. If you personally do not leave a review on this topic, others will have nothing to read.

Part Zodak tablets active ingredient included cetirizine dihydrochloride , as well as additional components: corn starch, lactose monohydrate, magnesium stearate, povidone 30. The tablet shell consists of macrogol 6000, hypromellose 2910/5, talc, titanium dioxide, simethicone emulsion SE4.

Part products in the form of syrup active ingredient included cetirizine dihydrochloride , as well as additional substances – propyl parahydroxybenzoate, propylene glycol, methyl parahydroxybenzoate, , sodium acetate trihydrate, sodium saccharinate dihydrate, flavoring, glacial acetic acid, water.

The drug is in the form of drops contains active ingredientcetirizine dihydrochloride and additional substances: propyl parahydroxybenzoate, methyl parahydroxybenzoate, propylene glycol, glycerol, sodium acetate trihydrate, sodium saccharinate dihydrate, glacial acetic acid, water.

Release form

The medicine is available in tablets, as well as in the form of syrup and drops.

Zodak tablets white or almost white, oblong in shape, with a score on one side of the tablet. They are contained in blisters of 7 or 10 pieces. Blisters are placed in cardboard packs.

Syrup Zodak transparent, it can be completely colorless or have a light yellow tint. Packaged in 100 ml dark glass bottles. A bottle and a measuring spoon are placed in a cardboard box.

Drops Zodak transparent, they can be completely colorless or have a light yellow tint. Contained in 20 ml dark glass bottles, in addition to the bottle, a dropper cap is placed in a cardboard box.

pharmachologic effect

This medicine is antiallergic a second-generation agent with a prolonged effect. The summary of the medicine indicates that the active component cetirizine belongs to the group of competitive histamine antagonists. The substance blocks H1- histamine receptors, but at the same time has almost no antiserotonin and anticholinergic effect. It has a pronounced antiallergic effect, while acting as antiexudative And antipruritic means.

The use of the drug in a therapeutic dosage does not lead to a sedative effect on the body and does not cause.

Pharmacokinetics and pharmacodynamics

Rapid absorption occurs after tablets, drops or syrup are taken orally active substance from the gastrointestinal tract. Highest concentration active component observed 30-60 minutes after taking the medicine.

Eating does not have a significant effect on the degree of absorption, but if the drug was taken during a meal, the rate of its absorption decreases slightly.

If Zodak is taken for 10 days at a dose of 10 mg, the drug does not accumulate in the body.

The main part is excreted unchanged by the kidneys. After the drug has been taken once, the half-life is approximately 10 hours. When taking the medicine by children from 2 to 12 years old, the half-life is reduced to 5-6 hours.

If the patient has impaired renal function or is on , the half-life becomes three times longer, and clearance also decreases by 70%.

Indications for use

Zodak's medicine different forms release is prescribed for the following conditions and diseases:

• and, both seasonal and year-round;
• (hay);
• allergic dermatosis itchy;
• hives (also chronic idiopathic urticaria);

Contraindications

Some contraindications to the use of Zodak are also identified:

• child's age up to 6 years (when taking drops and syrup - for children under 1 and 2 years old, respectively);
• severe sensitivity to the components of the product.

Zodak should be prescribed with caution to people with chronic , as well as elderly patients.

Side effects

As a rule, the drug is well tolerated. But sometimes in the process of taking the drug, some side effects may appear, for which Zodak tablets, as well as other forms of the drug, should be taken with caution.

The following side effects are possible:

• digestive system : , dry mouth;
• nervous system : fatigue, agitation, , state of drowsiness, .
• allergic manifestations : urticaria, skin rash, angioedema.

Instructions for use of Zodak (Method and dosage)

Zodak medicine should be used only after a doctor’s prescription to prevent complications. The drug is intended for oral administration, while food intake does not matter.

Zodak tablets, instructions for use

The tablets are swallowed whole, washed down with water. Children over 12 years of age and adults receive 1 tablet. 1 per day. Children aged 6 to 12 years receive 1 tablet per day or half a tablet in the morning and evening. It is important that the dosage of the drug for elderly patients is prescribed by a doctor. The dosage of tablets is also determined individually for patients with impaired renal function.

Zodak syrup, instructions for use

Adult patients and children over 12 years of age receive 2 scoops of the drug once a day. Patients aged 6 to 12 years receive 2 scoops of the drug once a day or 1 scoop in the morning and evening. Patients from 2 to 6 years old should receive 1 measuring spoon once a day or half a spoon in the morning and evening. For people with renal failure, the dose should be halved. Elderly people with normal kidney function may not need dose adjustments.

When using the drug, you should adhere to the rules for using the safety cap. If other drugs (tablets, ointments, etc.) are used in parallel, you should first consult a doctor.

Zodak drops, instructions for use

Drops are used internally; before taking them internally, you need to dissolve the drops in liquid. Adults and children over 12 years of age should take 20 drops of Zodak once a day. It is recommended to take the product in evening time. Children aged 6 to 12 years should take 20 drops of the drug once a day or 10 drops of the drug in the morning and in the evening. Children from 1 to 2 years old receive 5 drops twice a day. For people with kidney failure, the dosage of Zodak drops is halved. The abstract for the drops indicates that in old age patients with healthy kidneys receive the usual dose. Please note that the medicine bottle is closed with a safety cap.

Overdose

In case of a drug overdose, the following may occur: negative manifestations: sensation lethargy And drowsiness, headaches, high fatigue And weakness , . May develop irritability , also noted urinary retention, dry mouth .

In case of overdose, it is indicated to carry out symptomatic treatment. There is nothing specific. Gastric lavage is used, taking pills is indicated .

Interaction

If, while taking Zodak for allergies, the patient has any other diseases, it is important to consider the likelihood of interaction.

Zodak is a second-generation antiallergic drug, which is prescribed for manifestations of allergies to alleviate the patient’s condition and get rid of the symptoms of an allergic reaction.

At the same time, experts do not recommend combining Zodak and alcohol. This combination can lead to side effects. Most often, when taken simultaneously, lethargy and a desire to sleep appear.

The main active ingredient of the drug is cetirizine dihydrochloride. It is he who negatively affects the body's reactions caused by external stimuli. Upon contact with an allergen, histamine begins to be produced there, which causes unpleasant signs allergies (itching, sneezing, tearing, etc.)

Zodak suppresses histamine production by blocking nerve endings. The medicine is most effective at the initial stage of contact with the allergen.

Also this pharmacological agent can reduce capillary permeability, and this prevents the occurrence of bronchospasms. Experts recommend taking the product in advance, before contact with an external irritant occurs.

Today, the medicine can be seen in three dosage forms: syrup, tablets and drops. Syrup and drops are great for small children, while tablets are great for adults.

The medication is not addictive. It also does not have a sedative effect.

When is it used?

The main indications for taking the drug are:

• allergic rhinitis of seasonal and year-round nature;
• dermatitis and dermatoses caused by allergies;
• hives;
• hay fever (hay fever);
• Quincke's edema.

The action begins a quarter of an hour after ingestion, and the effectiveness lasts for about 24 hours.

Reviews from patients indicate that the medication is indeed quite effective, especially during the spring flowering period, when many experience allergies.

How to use?

Zodak tablets are allowed to be taken at any time of the day without reference to meals. They should be swallowed whole, with plenty of clean water. At acute manifestations In case of an allergic reaction, doctors advise taking pills at the same time of day, for example, at 8 am and 8 pm.

Adults and children over 12 years of age take one tablet per day. You can split the tablet into two and take it twice a day.

For children younger age It is more convenient to take drops. The medicine should be taken once every 24 hours, 20 drops. Children 1-2 years old are given the medicine 5 drops twice a day, 6-12 years old - 10 drops twice a day.

Syrup is not as popular as tablets or drops. It can be consumed by both children and adults, two scoops per day. Its advantage is that even people with diabetes mellitus, because It contains a sweetener, not sugar.

Contraindications

Zodak should not be drunk in the following cases:

• pregnancy and lactation;
• individual intolerance to the main active ingredient or additional components;
• child's age up to one year;
• non-allergic cough;
• heavy chronic diseases kidneys, liver;
• disorders of the kidneys;
• combined use with medications that depress the central nervous system.

Compatibility of medication and alcoholic beverages

Like any other medicine, you should not try to combine this antiallergic drug with alcoholic drinks. Allowed only if the amount of alcohol does not exceed 0.5 g/l in the blood. In this case, you should refrain from controlling vehicle and work requiring concentration.

Adverse reaction after simultaneous use

During simultaneous use of the drug and ethyl alcohol A disulfiram-like reaction may occur. The components of the product react with ethanol molecules and cause intoxication. It may manifest itself with the following symptoms:

• vomiting and nausea;
• skin redness;
• increased body temperature;
• high blood pressure;
• tachycardia;
• hard breath;
• headache;
• limb spasms;
• acute pain in the stomach;
• swelling;
• fainting state.

Also, in some cases, ethyl alcohol inhibits the work of the medicine, as a result of which free histamines continue to be produced and intensify the signs of the disease.

To avoid the development of possible negative consequences You should completely stop drinking alcohol while taking the drug.

IN medical practice Cases have been recorded in which patients with a disease such as alcoholism fell into a coma after taking antihistamines and large amounts of ethyl alcohol.

What to do if there is a violation?

In cases where alcohol was consumed during treatment, you must:

1. Stop drinking alcohol.
2. Drink as much as possible over the next 4 hours a large number of water.
3. Carefully read the contraindications in the instructions for use of the medicine and follow them.
4. If this happens only once and the dose of alcohol consumed is small, the harm caused to health will be minimal.
5. If your health suddenly worsens, you should seek help from a doctor as soon as possible.

Remember, no matter what dosage form the drug was taken in, its combination with alcohol can cause negative consequences.

How soon can you drink alcohol?

Drinking alcohol-containing drinks is allowed in minimum quantity one day after the drug was taken.

If the doctor prescribed a course of treatment or the drug was used by the patient for several days (weeks) in a row, then drink alcoholic drinks permitted after at least three days, in some cases after a month. This is due to the fact that drug substances are able to accumulate in the tissues of the body for a certain time and, if ethyl alcohol enters, they will react with its molecules. Such compatibility can lead to deterioration in well-being.

Name: Zodac

Pharmachologic effect:
Zodak is a 2nd generation antiallergic drug with a prolonged effect. The active ingredient of the drug is cetirizine dihydrochloride, a selective blocker of peripheral H1 receptors. Does not have significant antiserotonin and anticholinergic effects. When used in therapeutic doses, Zodak does not cause sedation, including drowsiness. The active substance of Zodak affects the histamine-dependent - early phase of allergic reactions, as well as the late cellular phase. Under the influence of cetirizine, the release of histamine from basophils and mast cells is inhibited, and the migration of eosinophils and other cells is reduced. When taking 5–60 mg of cetirizine, linear kinetics are observed. The total volume of distribution is 0.50 l/kg. The half-life of the active substance is 10 hours. The amount of absorption is not affected by food intake, but the rate of absorption of cetirizine is reduced.
There was no accumulation effect when taking a dose of 10 mg every day for 10 days. The maximum concentration in blood plasma after reaching equilibrium concentration is 300 ng/ml, which is achieved after 60±30 minutes. 93±0.3% of cetirizine is bound by blood proteins. It has no effect on the binding of warfarin to plasma proteins. It does not undergo active metabolic transformation during the initial passage through the liver. Approximately 2/3 of cetirizine is excreted unchanged in the urine. A study on volunteers revealed the absence of pharmacokinetic differences in both AUC and maximum concentration values. No differences in pharmacokinetic parameters were observed in adults of different racial backgrounds. The bioavailability of the active substance is the same for all dosage forms of the drug: syrup, drops and tablets.

Indications for use:
· Therapy of itching and urticaria of various origins, including urticaria accompanied by fever (chronic idiopathic urticaria);
· symptomatic treatment of allergic seasonal rhinitis and year-round allergic rhinitis;
· symptomatic treatment of allergic conjunctivitis.

Mode of application:
Zodak tablets
The tablet is taken with water, regardless of food. Do not chew! For adults and children over 12 years of age – 10 mg/day (1 tablet) in 1 dose.
In pediatrics: children from 6 to 12 years old - 5 mg / day (1/2 tablet) 2 times / day, 10 mg of Zodak can be taken once a day.

Zodak-drops
For adults and children over 12 years old – 10 mg (20 drops) 1 time per day. 1 ml of the drug contains 20 drops.
In pediatrics: from the first days of life to 2 years – 5 drops (2.5 mg) 2 times / day; from 2 to 6 years – 5 drops (2.5 mg of cetirizine) 2 times / day, 10 drops (5 mg) can be used
1 r/day; from 6 to 12 years - 10 drops (5 mg) 2 times / day, you can take 20 drops (10 mg) 1 time / day.

Zodak syrup
For adults and children over 12 years old – 10 mg (2 scoops) 1 time per day. 1 measuring spoon contains 5 ml of Zodak syrup. The spoon is equipped with divisions: ¼ - corresponds to 1.25 ml of syrup and ½ - 2.5 ml.
In pediatrics: from 1 to 2 years – 2.5 mg (half a measuring spoon) 2 times / day; from 2 to 6 years - 2.5 mg (half a measuring spoon) 2 times / day, you can take 5 mg (1 measuring spoon) 1 time / day; from 6 to 12 years – 5 mg (1 measuring spoon) 2 times / day, you can take 10 mg (2 measuring spoons) 1 time / day.

Treatment of elderly patients
In the case of normally functioning kidneys, there is no need to reduce the dosage.

Treatment of patients with impaired renal function
In case of moderate or severe impairment of renal function, individual intervals for taking Zodak should be established, which depends on the severity of renal failure: for minor impairment (creatinine clearance - 50–79 ml/min) - there is no need for dose adjustment and changing the interval between doses; for mild disorders (creatinine clearance 30–49 ml/min) – 5 mg/day as usual; for severe disorders (creatinine clearance ≤ 30 ml/min) – 10 mg 1 time per day after 2 days; in the terminal stage, if there are contraindications to hemodialysis (creatinine clearance ≤ 10 ml/min), the use of Zodak is contraindicated.
The dose of cetirizine for children with renal insufficiency is calculated individually, based on body weight and creatinine clearance level.

Treatment of patients with liver dysfunction
There is no need to reduce the dosage.

Side effects:
Unlike antihistamines of previous generations, which belong to the group of H1 receptor antagonists, the active substance of Zodak penetrates the blood-brain barrier in small quantities, so the development of a sedative effect is not expressed or expressed to a very mild degree. Although cetirizine acts selectively on peripheral H1 receptors, the anticholinergic effect is weak, but there have been reports of ocular accommodation disturbances, difficulty urinating, paradoxical stimulation of the central nervous system and a feeling of dry mouth.

From the central and peripheral nervous system:fatigue, drowsiness, dizziness and headache; paradoxical stimulation of the nervous system - in isolated cases.
From the hepatobiliary system:an increase in bilirubin content and liver enzyme activity (these side effects are transient and disappeared after discontinuation of the drug).

Contraindications:
Common to all dosage forms:
· a history of hypersensitivity to hydroxyzine or cetirizine or to any other ingredients of Zodak;
· During pregnancy and breastfeeding;
· renal failure with creatinine clearance less than 10 ml/min.

For tablets – age up to 6 years.
For syrup – age up to 1 year.

Pregnancy:
Zodak is contraindicated during pregnancy in all trimesters. If Zodak is prescribed to a nursing mother, breastfeeding should be temporarily stopped.

Interaction with other drugs:
Studies of the pharmacokinetic parameters of the interaction of cetirizine with cimetidine, pseudoephedrine, ketoconazole, azithromycin and erythromycin did not reveal. There is a slight decrease in the clearance of cetirizine to 16% when combined with repeated doses of theophylline at a dosage of 400 mg/day. Moreover, with this combination, the excretion of theophylline does not change.

Studies of pharmacodynamic parameters when combining cetirizine with glipizide, diazepam, azithromycin, theophylline, ketoconazole, erythromycin and pseudoephedrine did not reveal any adverse clinically significant interactions. Thus, the combination of the drug with ketoconazole or macrolides did not cause clinically significant changes in the electrocardiographic profile. It was also found that the active substance of Zodak does not affect the ability of warfarin to bind to blood proteins. When simultaneous ingestion of food with cetirizine, the volume of absorption does not change, but the rate of absorption decreases.

Overdose:
If the recommended dose of Zodak is exceeded, symptoms develop, mainly associated with changes in the central nervous system, and anticholinergic effects of cetirizine are also likely. As a result of exceeding the dose by 5 times, the following symptoms of overdose have been reported: diarrhea, agitation, dizziness, nausea, fatigue, dilated pupils, headache, itching, sedation, nervousness, drowsiness, tachycardia, stupor, tremor and urinary retention.
No specific antidote has been identified. In case of overdose, supportive and symptomatic therapy is used. Immediately after taking a large dose, gastric lavage is recommended. Hemodialysis is not effective because cetirizine is mostly bound to blood proteins.

Release form:
Zodak tablets – 10 mg, 5 doses; 10; thirty; 60; 90 pieces in blister pack. The tablets are white, oblong, biconvex, scored on one side.
Zodak drops for internal use – 10 mg in 1 ml, in 20 ml bottles. The drops are transparent, without color or with a slight yellow tint.
Zodak syrup – 5 mg/ml, 100 ml bottle. The syrup is transparent, without color or with a slight yellow tint. Has a characteristic banana smell.

Storage conditions:
At room temperature. Approved for over-the-counter release.

Compound:
Zodak tablets

Inactive ingredients: corn starch, lactose monohydrate, povidone, hydroxypropyl methylcellulose, titanium dioxide, talc, magnesium stearate, macrogol, dimethicone emulsion.

Zodak-drops
Active substance: cetirizine.
Inactive substances: propylparaben, methylparaben, glycerol 85%, sodium acetate, sodium saccharin, acetic acid, propylene glycol, purified water.

Zodak syrup
Active substance: cetirizine dihydrochloride.
Inactive ingredients: propylparaben, methylparaben, propylene glycol, glycerol 85%, sorbitol syrup, sodium acetate, sodium saccharin, banana flavor, acetic acid, purified water.

Additionally:
Tests have shown that Zodak has no clinically significant interaction with alcohol (in the case of a blood alcohol content of 0.5 g/l). However, it is not recommended to drink alcohol while taking Zodak. It is recommended to exercise caution for people whose activities involve increased demands for attention and quick reactions (drivers, machinists, machine maintenance, work at height, etc.). They also should not exceed the dose prescribed by the doctor.

Attention!
Before using the drugZodakyou should consult your doctor. This instruction instructions for use are provided in free translation and are intended for informational purposes only. For more complete information, please refer to the manufacturer's instructions.
http://www.piluli.kharkov.ua/drugs/drug/zodac/